Abstract
Somatic mutations and copy number alterations are the
basis for cancer development and progression, and their
identification is crucial for the development of novel
diagnostics and therapies. Identification of somatic
alterations has been greatly sped up by recent
technological progresses, such as CGH and SNP arrays, and
high-throughput DNA sequencing. An immense set of genomic
data will be available in the near future. It will be
mandatory to overlay and integrate multiple levels of
genomic and functional information, aiming for the bigger
picture of cancer biology. The ultimate goal will be a
detailed understanding of pathways and mechanisms altered
in cancer, leading the way to improved therapeutic
strategies.
Original language | English |
---|---|
Pages (from-to) | 269-276 |
Journal | Drug Discovery Today: Disease Mechanisms |
Volume | 4 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2007 |
MoE publication type | B1 Article in a scientific magazine |